Results in The Journal of American Dental Association showed the non-opioid combination provided superior pain relief during ...
Treatment with XG005 resulted in statistically significant and clinically meaningful reduction in post-surgical pain ...
A trial with XG005 met it's primary and secondary endpoints, demonstrating a statistically significant reduction in ...
Taiwanese pharmaceutical company Xgene Pharmaceutical announced that its non-opioid analgesic drug XG005 has reduced acute pain in patients after surgery in a Phase IIb study[MV1] . The placebo ...
“I have not seen any analgesics showing such great efficacy ... “There is a substantial need for more efficacious, safer, non-opioid treatment for acute pain, as many patients are unable ...
For those patients who required rescue analgesics, XG005 increased the time to first use of rescue by 8-fold and it reduced the total amount of opiate consumption medication by 4-fold in a high ...
Xgene Pharmaceutical announced additional insights into the positive results of a multiple-center, placebo-controlled, dose-ranging Phase 2b study (registration number: NCT06017999) in patients ...
For those patients who required rescue analgesics, XG005 increased the time to first use of rescue by 8-fold and it reduced the total amount of opiate consumption medication by 4-fold in a high dose ...